EHA 2018 Conference Review - focus on MM, reviewed by Associate Professor Philip Campbell

In this review:

Autologous SCT safe and effective in older myeloma patients
D-VMP in elderly, transplant-ineligible, newly diagnosed MM
Efficacy and MRD data by risk status in newly diagnosed MM treated with KRD or KCD
Maintenance ±consolidation in newly diagnosed, transplant-eligible MM
Triplet VTD therapy before and after double SCT in newly diagnosed MM
Adding busulfan to melphalan in high-risk MM
Once vs. twice weekly carfilzomib + dexamethasone in relapsed/refractory MM
Adding elotuzumab to pomalidomide/dexamethasone for relapsed/refractory MM
Cytotoxicity of MM cells using daratumumab plus high-affinity CD16-expressing NK cells
Effect of daratumumab on normal plasma cells, Igs and vaccine responses in pretreated MM

Please login below to download this issue (PDF)